Bispecific antibodies (BsAbs) are antibodies with two binding sites directed at two different
antigens or two different epitopes on the same antigen. The clinical therapeutic effects of …

Immuno-oncology approaches have entered clinical practice, with tremendous progress
particularly in the field of T cell-engaging therapies over the past decade. Herein, we provide …

Background Patients with relapsed or refractory B-cell non-Hodgkin lymphoma have few
treatment options. We aimed to establish the safety and recommended phase 2 dose of …

The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of
ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk …

During the last decade the field of cancer immunotherapy has witnessed impressive
progress. Highly effective immunotherapies such as immune checkpoint inhibition, and T …

Emerging data from chimeric antigen receptor (CAR) T-cell trials in B-cell malignancies
demonstrate that a common mechanism of resistance to this novel class of therapeutics is …

PURPOSE CD19-targeted chimeric antigen receptor T cells (CD19-CAR) and blinatumomab
effectively induce remission in relapsed or refractory B-cell acute lymphoblastic leukemia …

T-cell-engaging bispecific antibodies (BsAbs) simultaneously bind to antigens on tumour
cells and CD3 subunits on T cells. This simultaneous binding results in the recruitment of T …

Harnessing the power of immune cells, especially T cells, to enhance anti-tumor activities
has become a promising strategy in clinical management of hematologic malignancies. The …

Progress in the research and therapy of adult acute lymphoblastic leukemia (ALL) is
accelerating. This analysis summarizes the data derived from the clinical trials conducted at …